LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Listă Acțiuni・Exelixis Inc

Exelixis Inc

Închisă

SectorSănătate

50.42 -1.87

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

50.31

Maxim

51.02

Indicatori cheie
By Trading Economics
Venit	-34M 210M
Vânzări	12M 611M
P/E Medie Sector	16.606 50.102
EPS	0.87
Marjă de profit	34.457
Angajați	1,077
EBITDA	15M 258M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	-5.51% downside

Dividende
By Dow Jones
Următoarele câștiguri	27 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.4B 13B
Deschiderea anterioară	52.29
Închiderea anterioară	50.42

Sentimentul știrilor

By Acuity

50%

124 / 344 Clasament în Healthcare

Exelixis Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mai 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 mai 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 mai 2026, 22:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 mai 2026, 23:08 UTC

Achiziții, Fuziuni, Preluări

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mai 2026, 20:53 UTC

Câștiguri

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mai 2026, 20:11 UTC

Câștiguri

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 19:47 UTC

Câștiguri

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mai 2026, 19:05 UTC

Achiziții, Fuziuni, Preluări

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mai 2026, 18:12 UTC

Achiziții, Fuziuni, Preluări

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mai 2026, 17:55 UTC

Câștiguri

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mai 2026, 17:00 UTC

Câștiguri

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29 mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Exelixis Inc Așteptări

Obiectiv de preț

By TipRanks

-5.51% jos

Prognoză pe 12 luni

Medie 47.7 USD -5.51%

Maxim 56 USD

Minim 40 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruExelixis Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 11 analiști care au acordat evaluări ale acțiunilor Exelixis Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

124 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.